These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. [Ecstasy, new psychotropic drugs]. Djezzar S Soins Psychiatr; 2009; (262):35-7. PubMed ID: 19579485 [No Abstract] [Full Text] [Related]
24. Five-year trends in self-reported recreational drugs associated with presentation to a UK emergency department with suspected drug-related toxicity. Wood DM; Greene SL; Dargan PI Eur J Emerg Med; 2013 Aug; 20(4):263-7. PubMed ID: 22850087 [TBL] [Abstract][Full Text] [Related]
25. Weekly gamma-hydroxybutyrate exposure sensitizes locomotor hyperactivity to low-dose 3,4-methylenedioxymethamphetamine in rats. van Nieuwenhuijzen PS; Li KM; Hunt GE; McGregor IS Neuropsychobiology; 2009; 60(3-4):195-203. PubMed ID: 19893336 [TBL] [Abstract][Full Text] [Related]
28. Rave drugs: pharmacological considerations. Klein M; Kramer F AANA J; 2004 Feb; 72(1):61-7. PubMed ID: 15098519 [TBL] [Abstract][Full Text] [Related]
29. Sildenafil (Viagra) and club drug use in gay and bisexual men: the role of drug combinations and context. Halkitis PN; Green KA Am J Mens Health; 2007 Jun; 1(2):139-47. PubMed ID: 19482790 [TBL] [Abstract][Full Text] [Related]
30. Sedative and hypothermic effects of gamma-hydroxybutyrate (GHB) in rats alone and in combination with other drugs: assessment using biotelemetry. van Nieuwenhuijzen PS; McGregor IS Drug Alcohol Depend; 2009 Aug; 103(3):137-47. PubMed ID: 19446408 [TBL] [Abstract][Full Text] [Related]
32. Relative abuse liability of gamma-hydroxybutyric acid, flunitrazepam, and ethanol in club drug users. Abanades S; Farré M; Barral D; Torrens M; Closas N; Langohr K; Pastor A; de la Torre R J Clin Psychopharmacol; 2007 Dec; 27(6):625-38. PubMed ID: 18004131 [TBL] [Abstract][Full Text] [Related]
33. Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users: the longitudinal perspective. Thomasius R; Zapletalova P; Petersen K; Buchert R; Andresen B; Wartberg L; Nebeling B; Schmoldt A J Psychopharmacol; 2006 Mar; 20(2):211-25. PubMed ID: 16510479 [TBL] [Abstract][Full Text] [Related]
35. Profiles of club drug users in treatment. Maxwell JC; Spence RT Subst Use Misuse; 2005; 40(9-10):1409-26. PubMed ID: 16048825 [TBL] [Abstract][Full Text] [Related]
36. Enhanced intensity dependence and aggression history indicate previous regular ecstasy use in abstinent polydrug users. Wan L; Baldridge RM; Colby AM; Stanford MS Prog Neuropsychopharmacol Biol Psychiatry; 2009 Nov; 33(8):1484-90. PubMed ID: 19703509 [TBL] [Abstract][Full Text] [Related]
37. Human psychobiology of MDMA or 'Ecstasy': an overview of 25 years of empirical research. Parrott AC Hum Psychopharmacol; 2013 Jul; 28(4):289-307. PubMed ID: 23881877 [TBL] [Abstract][Full Text] [Related]
38. Reduced memory and attention performance in a population-based sample of young adults with a moderate lifetime use of cannabis, ecstasy and alcohol. Indlekofer F; Piechatzek M; Daamen M; Glasmacher C; Lieb R; Pfister H; Tucha O; Lange KW; Wittchen HU; Schütz CG J Psychopharmacol; 2009 Jul; 23(5):495-509. PubMed ID: 18635709 [TBL] [Abstract][Full Text] [Related]
39. Club drugs: review of the 'rave' with a note of concern for the Indian scenario. Chakraborty K; Neogi R; Basu D Indian J Med Res; 2011 Jun; 133(6):594-604. PubMed ID: 21727657 [TBL] [Abstract][Full Text] [Related]
40. Recognition and management of complications of new recreational drug use. Ricaurte GA; McCann UD Lancet; 2005 Jun 18-24; 365(9477):2137-45. PubMed ID: 15964451 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]